Newbypass Completes Weight Loss Studies

Newbypass Completes Weight Loss Studies

SAN GABRIEL, Calif.NewbypassInternational Inc. announced the completion of two company studies conducted byDavid Chen, Ph.D., in China. In the first study, Chen investigated the effectsof Newbypass CoroLex, an extract from banaba leaves, on sugar levels inType II diabetic mice. During the 60 day study, the control mice showed anincrease in blood glucose levels, while those receiving CoroLex hadsignificantly lower blood glucose levels by the 35th day of treatment.

The second study focused on the efficacy and safety ofWKBphasell, the companys trademarked white kidney bean (Phaseolousvulgaris) extract. In a double blind,placebo-controlled study of 56 adults, those taking WKBphasell lost an averageof 7.67 pounds in 30 days, compared to a weight loss of only 1 pound in 30 daysin the placebo group. Subjects in the treatment group also lost, on average,over 11.2 percent of body fat mass with no loss of lean body mass.

For more information, visit www.newbypass.com or Booth #1368at SupplySide West.